<DOC>
	<DOCNO>NCT00145665</DOCNO>
	<brief_summary>The aim study obtain information FLT use PET-scan marker proliferation colorectal liver metastasis , risk recurrence identify noninvasive way , concern patient resectable colorectal liver metastasis . The hypothesis study high uptake FLT liver metastasis good correlation proliferation rate metastasis . This rate relate risk recurrence .</brief_summary>
	<brief_title>The Role Fluorothymidine Positron Emission Tomography ( FLT-PET ) Proliferation Colorectal Liver Metastases</brief_title>
	<detailed_description>Aim Study : Validation FLT-PET proliferation marker colorectal liver metastasis , risk recurrence patient resect colorectal liver metastasis assess noninvasive method . Study Design : Validation study ( n=40 ) determine correlation quantitative FLT-PET ( study determine resection colorectal liver metastasis ) histologically determine proliferation index resect specimen metastasis ( 'golden standard ' ) . If correlation establish , correlation proliferation recurrence rate study also ( n=80 ) . Study Population : Patients colorectal liver metastasis . Intervention : FLT-PET scan Scientific Basis Study : Several report show presence absence extrahepatic disease determine prognostic factor . Patients extrahepatic disease rarely suit resection liver metastasis . Recently several paper describe proliferation index liver metastases another determine prognostic factor . Patients high proliferation factor bad prognosis . For determine factor , seem PET diagnostics play essential role contribute good selection patient suitable resection . Diagnostics Proliferation : Seeing proliferation rate preoperatively determine without biopsy ( contraindicate due dissemination ) , patient colorectal liver metastasis ( sign extrahepatic deposit ) resect , without knowledge proliferation . FLT marker visualize proliferation thus seem ideal candidate determine proliferation rate noninvasive method . As yet validation study FLT-PET colorectal liver metastases describe . Evaluation : Quantitative histologic data correlate quantitative FLT-PET data . If correlation high 0.85 , correlation establish . If correlation find , inclusion patient extend 40 80 patient , see give u opportunity correlate clinical data histological data . ( alpha = 0.05 , one-sided , beta = 0.90 , assume acceptable difference sensitivity test 0 unacceptable difference 0.02 ) . If correlation significant , new study propose introduction neoadjuvant chemotherapy , selection determine basis proliferation rate .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Colorectal liver metastasis deem resectable threephase compute tomography ( CT ) scan liver No evidence extrahepatic disease CT chest abdomen possible fluorodeoxyglucose ( FDG ) PET ( part surgical workup ) No evidence local recurrence second primary colorectal tumor colonoscopy colonography Primary colorectal tumor radically remove Informed consent Pregnancy Recent chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>FLT-PET</keyword>
	<keyword>colorectal liver metastasis</keyword>
	<keyword>proliferation</keyword>
	<keyword>proliferation marker</keyword>
	<keyword>recurrence</keyword>
</DOC>